Report: Products, Technologies and Markets in the U.S. and Europe in the Clinical Management of Obesity TOC

Executive Summary

Section 1: Introduction

1.1 Overview
1.2 Definitions
1.3 Clinical Background: 1.3.1 Prevalence in the US Population; 1.3.2 Prevalence of Obesity Worldwide; 1.3.2.1 Europe; 1.3.2.2 Japan; 1.3.2.3 China; 1.3.2.4 Developed Nations vs. Developing Nations
1.4 Patient Population Segmentation: 1.4.1 Adults; 1.4.2 Adolescents; 1.4.3 Children
1.5 Overweight, Obesity and Morbidity: 1.5.1 The Multifactorial Causes of Obesity; 1.5.1.1 The Appetite Regulatory System?Facts and Theories; 1.5.1.1.1 Insulin; 1.5.1.1.2 Leptin: The Ups and Downs of a Promising Lead; 1.5.1.1.3 Ghrelin; 1.5.1.1.4 Peptide YY & the Y2 Receptor; 1.5.1.1.5 AMPK; 1.5.1.1.6 Role of the Hypothalamus; 1.5.1.1.7 Melanocortins & Serotonin; 1.5.1.2 The Bodyfs Fight to Retain Fat; 1.5.1.3 Body Mass Index (BMI); 1.5.1.4 Genetic Roots of Obesity; 1.5.1.4.1 Congenital Leptin Deficiency; 1.5.1.4.2 Genetic Association Studies; 1.5.1.4.3 Genetic Testing For Obesity; 1.5.2 Obesity, Lifestyle and the eObesogenicf Environment; 1.5.2.1 Feeding Control; 1.5.2.2 Energy Efficiency; 1.5.2.3 Adipose Tissue Biology; 1.5.2.4 Abdominal Girth as a Warning Sign; 1.5.3 Metabolic Syndrome, or Syndrome X; 1.5.4 Binge Eating Disorder (BED); 1.5.5 Night Eating Syndrome (NES); 1.5.6 Why Treat Obesity?

Section 2: Weight loss management approaches

2.1 Surgical Approaches: 2.1.1 Background and Professional Certification Efforts; 2.1.2 Gastric Bypass, Mini Gastric Bypass and Laparoscopic Surgery; 2.1.2.1 Gastric Bypass, or Roux-en-Y Surgery; 2.1.2.2 Mini Gastric Bypass; 2.1.2.3 Laparoscopic Surgery; 2.1.3 Biliopancreatic Diversion/Duodenal Switch (BPD/DS); 2.1.4 Two-Stage Weight Loss Surgery; 2.1.5 Vertical Banded Gastroplasty (VBG); 2.1.6 Adjustable Gastric Band (AGB) Surgery; 2.1.7 Internal or Implantable Gastric Stimulation (IGS) Device; 2.1.8 Gastric Balloon; 2.1.9 Radio-frequency Antralplasty
2.2 Pharmaceutical Therapies: 2.2.1 Pancreatic Lipase Inhibitors; 2.2.2 Serotonin and Norepinephrine Reuptake Inhibitors; 2.2.3 Noradrenergic Anorectic Agents
2.3 Non-pharmacological Approaches
2.4 Medically Supervised Very Low Calorie Diets (VLCDs), Behavior Modification and Residential Programs
2.5 Weight Maintenance Approaches

Section 3: Impact of obesity

3.1 Obesity Treatments, Related Costs and Reimbursement
3.2 Impact Upon Business/Economy: 3.2.1 United Kingdom; 3.2.2 Impact Upon Insurance Costs; 3.2.3 Cost of Treatment of Obesity, versus Long-term Cost to Treat Related Conditions
3.3 The Government Enters the Fray: 3.3.1 USA; 3.3.1.1 Insurance and Mandated Coverage Bills; 3.3.1.2 Medicare Debates Gastric Bypass Surgery; 3.3.2 United Kingdom: NICE & Weight Management at the Primary Care Level; 3.3.3 France: The Caisse Nationale dfAssurance Maladie (CNAM)

Section 4: Market Assessment

4.1 Bariatric Surgery Devices: 4.1.1 United States and Canada; 4.1.2 Canada; 4.1.3 European Union; 4.1.3.1 United Kingdom; 4.1.3.2 France; 4.1.3.3 Germany; 4.1.3.4 Italy; 4.1.3.5 Spain; 4.1.3.6 Scandinavia; 4.1.4 Japan; 4.1.5 Rest of World (ROW)
4.2 Pharmaceuticals: 4.2.1 United States and Canada; 4.2.2 Pharmaceutical treatments in the Europe Union; 4.2.2.1 United Kingdom; 4.2.2.2 France; 4.2.2.3 Germany; 4.2.2.4 Italy; 4.2.2.5 Spain; 4.2.2.6 Scandinavia; 4.2.3 Japan; 4.2.4 Rest of World (ROW); 4.2.5 Developing Drugs for Tomorrow, While Maximizing Profits Today

Section 5: Opportunities

5.1 Drug & Device Market Opportunities
5.2 Durable Medical Equipment for the Bariatric Patient
5.3 Creating Mutually Beneficial Relationships
5.4 Focus on Education and Practice Consulting

Section 6: Selected Company Profiles

6.1 Abbott Laboratories
6.2 AdipoGenix
6.3 Amgen
6.4 Amylin Pharmaceuticals
6.5 AstraZeneca
6.6 Athersys, Inc.
6.7 Bayer AG
6.8 Biovitrum AB
6.9 CuraGen Corporation
6.10 DeCODE Genetics
6.11 DeveloGen AG
6.12 Ethicon Endo-Surgery/Johnson & Johnson
6.13 GenWay Biotech, Inc.
6.14 GlaxoSmithKline
6.15 Inamed Corporation
6.16 Ingenium Pharmaceuticals AG
6.17 IntraPace, Inc.
6.18 Johnson & Johnson
6.19 Manhattan Pharmaceuticals, Inc.
6.20 Merck & Co., Inc.
6.21 Metabolic Pharmaceuticals Ltd
6.22 Millennium Pharmaceuticals
6.23 Myriad Genetics
6.24 Nastech Pharmaceutical Company, Inc.
6.25 Pfizer, Inc.
6.26 Regeneron Pharmaceuticals
6.27 Roche (F Hoffman-La Roche Ltd)
6.28 Sanofi-Aventis
6.29 Speedel Group AG
6.30 Synovis Life Technologies Inc.
6.31 Transneuronix, Inc.
6.32 Vista Medical Technologies, Inc.
6.33 Wyeth Pharmaceuticals

Appendix: List of Companies

Appendix: List of ORGANIZATIONS

List of Exhibits

Exhibit 1-1: Elements Contributing to the Obesity Epidemic
Exhibit 1-2: Prevalence of Obesity, Percent of Population (2003)
Exhibit 1-3: WHO Graph of Obesity, 2004
Exhibit 1-4: Worldwide Total, Obese and Morbidly Obese, 2002-2013
Exhibit 1-5: Examples of Definitions Used and Age Groups Included in Surveys Reporting Prevalence of Obesity
Exhibit 1-6: Examples of Human Pleiotropic Obesity Syndromes
Exhibit 1-7: Leptinfs Role in the Body
Exhibit 1-8: Candidate Genes for Control of Appetite, Energy Expenditure, Usage of Nutrients and Body Fat Distribution
Exhibit 2-1: IFSO and Minimum Professional Requirements for Practicing Bariatric Surgeon
Exhibit 2-2: Gastric Bypass Surgery
Exhibit 4-1: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M)
Exhibit 4-2: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M)
Exhibit 4-3: Bariatric Surgery Devices, Total Market Forecast, 2002-2013
Exhibit 4-4: Medical Devices, Market Forecast, United States and Canada, 2002-2013
Exhibit 4-5: Bariatric Surgery Devices, Market Forecast, US and Canada, 2002-2013
Exhibit 4-6: US Obesity Treatment Medical Device Company Market Shares, 2013
Exhibit 4-7: Medical Devices, Market Forecast, European Union, 2002-2013
Exhibit 4-8: Medical Devices, Market Forecast, United Kingdom, 2002-2013
Exhibit 4-9: Bariatric Surgery Devices, Market Forecast, United Kingdom 2002-2013
Exhibit 4-10: Medical Devices, Market Forecast, France, 2002-2013
Exhibit 4-11: Bariatric Surgery Devices, Market Forecast, France, 2002-2013
Exhibit 4-12: Adjustable Gastric Band Device Market Shares, France, 2004
Exhibit 4-13: Medical Devices, Market Forecast, Germany, 2002-2013
Exhibit 4-14: Bariatric Surgery Devices, Market Forecast, Germany 2002-2013
Exhibit 4-15: Medical Devices, Market Forecast, Italy, 2002-2013
Exhibit 4-16: Bariatric Surgery Devices, Market Forecast, Italy 2002-2013
Exhibit 4-17: Medical Devices, Market Forecast, Spain, 2002-2013
Exhibit 4-18: Bariatric Surgery Devices, Market Forecast, Spain 2002-2013
Exhibit 4-19: Medical Devices, Market Forecast, Scandinavia, 2002-2013
Exhibit 4-20: Bariatric Surgery Devices, Market Forecast, Scandinavia 2002-2013
Exhibit 4-21: Medical Devices, Market Forecast, Japan, 2002-2013
Exhibit 4-22: Bariatric Surgery Devices, Market Forecast, Japan 2002-2013
Exhibit 4-23: Medical Devices, Market Forecast, Rest of World, 2002-2013
Exhibit 4-24: Bariatric Surgery Devices, Market Forecast, ROW 2002-2013
Exhibit 4-25: Total Pharmaceutical Sales, Market Forecast, 2002-2013
Exhibit 4-26: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013
Exhibit 4-27: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013
Exhibit 4-28: Obesity Drugs, Market Forecast, European Union, 2002-2013
Exhibit 4-29: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013
Exhibit 4-30: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013
Exhibit 4-31: Obesity Drugs, Market Forecast, France, 2002-2013
Exhibit 4-32: Obesity Drugs, Market Forecast, France, 2002-2013
Exhibit 4-33: Obesity Drugs, Market Forecast, Germany, 2002-2013
Exhibit 4-34: Obesity Drugs, Market Forecast, Germany, 2002-2013
Exhibit 4-35: Obesity Drugs, Market Forecast, Italy, 2002-2013
Exhibit 4-36: Obesity Drugs, Market Forecast, Italy, 2002-2013
Exhibit 4-37: Obesity Drugs, Market Forecast, Spain, 2002-2013
Exhibit 4-38: Obesity Drugs, Market Forecast, Spain, 2002-2013
Exhibit 4-39: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013
Exhibit 4-40: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013
Exhibit 4-41: Obesity Drugs, Market Forecast, Japan, 2002-2013
Exhibit 4-42: Obesity Drugs, Market Forecast, Japan, 2002-2013
Exhibit 4-43: Obesity Drugs, Market Forecast, ROW, 2002-2013
Exhibit 4-44: Obesity Drugs, Market Forecast, ROW, 2002-2013
Exhibit 5-1: Potential Market Alliances in Obesity
Exhibit 6-1: Abbott Laboratories 2003 Sales by Division
Exhibit 6-2: Aventis 2003 Consolidated Sales